Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this phase I/II trial, we will evaluate a novel combination of chemotherapy, used
concurrently with radiation therapy, in the preoperative therapy of locoregional carcinoma of
the esophagus and gastroesophageal junction. In the brief phase I portion of this trial, we
will determine whether 2 drugs (docetaxel/oxaliplatin) or 3 drugs
(docetaxel/oxaliplatin/capecitabine) can be used concurrently with radiation therapy. If the
3-drug regimen is tolerated, the phase II portion will proceed with this regimen. If the
3-drug combination is considered too toxic, the phase II study will proceed with
docetaxel/oxaliplatin in combination with radiation therapy.